Michael Cherny
Stock Analyst at Leerink Partners
(4.23)
# 445
Out of 5,242 analysts
122
Total ratings
58.89%
Success rate
12.74%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DOCS Doximity | Maintains: Outperform | $31 → $25 | $19.86 | +25.88% | 3 | May 14, 2026 | |
| MCK McKesson | Maintains: Buy | $1,040 → $1,000 | $754.68 | +32.51% | 16 | Apr 6, 2026 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $18 → $25 | $23.04 | +8.51% | 12 | Mar 16, 2026 | |
| TDOC Teladoc Health | Maintains: Market Perform | $8.5 → $5.5 | $6.48 | -15.12% | 2 | Feb 26, 2026 | |
| HSIC Henry Schein | Maintains: Market Perform | $75 → $87 | $73.20 | +18.85% | 3 | Feb 24, 2026 | |
| ACH Accendra Health | Maintains: Market Perform | $3 → $2.75 | $2.67 | +3.00% | 1 | Feb 20, 2026 | |
| XRAY DENTSPLY SIRONA | Upgrades: Buy | $13 → $17 | $9.84 | +72.76% | 9 | Feb 19, 2026 | |
| MEDP Medpace Holdings | Maintains: Market Perform | $575 → $485 | $421.87 | +14.96% | 2 | Feb 11, 2026 | |
| CVS CVS Health | Maintains: Buy | $100 → $95 | $93.28 | +1.84% | 12 | Jan 27, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $36.25 | +32.41% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $13 | $4.67 | +178.37% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $203 → $210 | $193.75 | +8.39% | 3 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $188 → $186 | $199.23 | -6.64% | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $28 | $25.64 | +9.20% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $3 | $1.42 | +111.27% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $23 | $23.77 | -3.24% | 11 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $163.38 | +71.38% | 3 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $171.50 | +44.61% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $115.09 | +121.57% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $264.75 | +3.87% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $257.42 | +1.00% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.52 | +217.46% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $0.626 | +8,286.58% | 2 | Jan 5, 2022 |
Doximity
May 14, 2026
Maintains: Outperform
Price Target: $31 → $25
Current: $19.86
Upside: +25.88%
McKesson
Apr 6, 2026
Maintains: Buy
Price Target: $1,040 → $1,000
Current: $754.68
Upside: +32.51%
Hims & Hers Health
Mar 16, 2026
Maintains: Market Perform
Price Target: $18 → $25
Current: $23.04
Upside: +8.51%
Teladoc Health
Feb 26, 2026
Maintains: Market Perform
Price Target: $8.5 → $5.5
Current: $6.48
Upside: -15.12%
Henry Schein
Feb 24, 2026
Maintains: Market Perform
Price Target: $75 → $87
Current: $73.20
Upside: +18.85%
Accendra Health
Feb 20, 2026
Maintains: Market Perform
Price Target: $3 → $2.75
Current: $2.67
Upside: +3.00%
DENTSPLY SIRONA
Feb 19, 2026
Upgrades: Buy
Price Target: $13 → $17
Current: $9.84
Upside: +72.76%
Medpace Holdings
Feb 11, 2026
Maintains: Market Perform
Price Target: $575 → $485
Current: $421.87
Upside: +14.96%
CVS Health
Jan 27, 2026
Maintains: Buy
Price Target: $100 → $95
Current: $93.28
Upside: +1.84%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $36.25
Upside: +32.41%
Jan 6, 2026
Upgrades: Outperform
Price Target: $13
Current: $4.67
Upside: +178.37%
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $193.75
Upside: +8.39%
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $199.23
Upside: -6.64%
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $25.64
Upside: +9.20%
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.42
Upside: +111.27%
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $23.77
Upside: -3.24%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $163.38
Upside: +71.38%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $171.50
Upside: +44.61%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $115.09
Upside: +121.57%
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $264.75
Upside: +3.87%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $257.42
Upside: +1.00%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.52
Upside: +217.46%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $0.626
Upside: +8,286.58%